Biotech firm Redx Pharma plans to delist from LSE AIM, aiming for better investor access as a private company.
Biotech firm Redx Pharma plans to delist from the London Stock Exchange's AIM market due to low liquidity, and aims to attract investors more easily as a private company. Redx Pharma's decision follows a trend of innovative biotechs opting for the US market, as companies such as Barinthus Biotherapeutics, Zura Bio, and OKYO Pharma have chosen to sell shares in New York or move their listings there.
April 02, 2024
5 Articles